CN106459025B - 6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式 - Google Patents

6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式 Download PDF

Info

Publication number
CN106459025B
CN106459025B CN201580025357.8A CN201580025357A CN106459025B CN 106459025 B CN106459025 B CN 106459025B CN 201580025357 A CN201580025357 A CN 201580025357A CN 106459025 B CN106459025 B CN 106459025B
Authority
CN
China
Prior art keywords
methyl
titanium dioxide
nitrile
isoquinolin
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201580025357.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459025A (zh
Inventor
E·L·P·谢克莱
R·L·多罗
J·B·斯佩里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN106459025A publication Critical patent/CN106459025A/zh
Application granted granted Critical
Publication of CN106459025B publication Critical patent/CN106459025B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580025357.8A 2014-05-15 2015-05-01 6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式 Expired - Fee Related CN106459025B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461993693P 2014-05-15 2014-05-15
US61/993,693 2014-05-15
US201562138037P 2015-03-25 2015-03-25
US62/138,037 2015-03-25
PCT/IB2015/053194 WO2015173684A1 (en) 2014-05-15 2015-05-01 Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile

Publications (2)

Publication Number Publication Date
CN106459025A CN106459025A (zh) 2017-02-22
CN106459025B true CN106459025B (zh) 2019-05-28

Family

ID=53276206

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580025357.8A Expired - Fee Related CN106459025B (zh) 2014-05-15 2015-05-01 6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式

Country Status (21)

Country Link
US (1) US9920043B2 (https=)
EP (1) EP3143019B1 (https=)
JP (1) JP6523782B2 (https=)
KR (1) KR101817889B1 (https=)
CN (1) CN106459025B (https=)
AU (1) AU2015260906B2 (https=)
CA (1) CA2891398C (https=)
CY (1) CY1123826T1 (https=)
DK (1) DK3143019T3 (https=)
ES (1) ES2845639T3 (https=)
HU (1) HUE052692T2 (https=)
IL (1) IL248918A0 (https=)
MX (1) MX371014B (https=)
PL (1) PL3143019T3 (https=)
PT (1) PT3143019T (https=)
RU (1) RU2698194C2 (https=)
SG (1) SG11201608320QA (https=)
SI (1) SI3143019T1 (https=)
TW (1) TWI553007B (https=)
WO (1) WO2015173684A1 (https=)
ZA (1) ZA201606796B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201609050UA (en) * 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
WO2023275715A1 (en) * 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838956A (zh) * 2003-08-22 2006-09-27 配体药物公司 作为雄激素受体调节剂化合物的6－环氨基－2－喹啉酮衍生物
CN101945853A (zh) * 2007-12-21 2011-01-12 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0089139A2 (en) 1982-03-16 1983-09-21 Beecham Group Plc Antibiotics, their preparation and use
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US20060142387A1 (en) 2003-06-10 2006-06-29 Rodolfo Cadilla Chemical compounds
MX368898B (es) 2012-12-03 2019-10-21 Pfizer Moduladores selectivos del receptor de androgenos novedosos.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1838956A (zh) * 2003-08-22 2006-09-27 配体药物公司 作为雄激素受体调节剂化合物的6－环氨基－2－喹啉酮衍生物
CN101945853A (zh) * 2007-12-21 2011-01-12 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用

Also Published As

Publication number Publication date
AU2015260906A1 (en) 2016-10-20
DK3143019T3 (da) 2021-01-04
CY1123826T1 (el) 2022-05-27
RU2016144671A3 (https=) 2018-06-15
TWI553007B (zh) 2016-10-11
ZA201606796B (en) 2018-04-25
ES2845639T3 (es) 2021-07-27
US9920043B2 (en) 2018-03-20
PT3143019T (pt) 2021-01-28
EP3143019B1 (en) 2020-12-16
EP3143019A1 (en) 2017-03-22
TW201546069A (zh) 2015-12-16
AU2015260906B2 (en) 2017-08-31
SI3143019T1 (sl) 2021-03-31
JP6523782B2 (ja) 2019-06-05
CA2891398C (en) 2019-09-24
KR20160144478A (ko) 2016-12-16
WO2015173684A1 (en) 2015-11-19
KR101817889B1 (ko) 2018-01-11
MX2016014999A (es) 2017-04-11
RU2016144671A (ru) 2018-06-15
CA2891398A1 (en) 2015-11-15
HUE052692T2 (hu) 2021-05-28
JP2015218166A (ja) 2015-12-07
CN106459025A (zh) 2017-02-22
SG11201608320QA (en) 2016-11-29
US20170073338A1 (en) 2017-03-16
PL3143019T3 (pl) 2021-03-22
MX371014B (es) 2020-01-10
IL248918A0 (en) 2017-01-31
RU2698194C2 (ru) 2019-08-23

Similar Documents

Publication Publication Date Title
JP2021105030A (ja) ニコチンアミドリボシドの結晶形
US12378194B2 (en) N, n-dimethyltryptamine salts and crystalline salt forms
RU2624446C2 (ru) Трициклические соединения, композиции, содержащие указанные соединения, и их применения
TW406077B (en) 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
AU2018303293B2 (en) Amorphous form of vilanterol trifenatate and processes for the preparation thereof
JP2018039807A (ja) 結晶形態の（Ｓ）−４−アミノ−Ｎ−（１−（４−クロロフェニル）−３−ヒドロキシプロピル）−１−（７Ｈ−ピロロ［２，３−ｄ］−ピリミジン−４−イル）ピペリジン−４−カルボキサミド
US8124640B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
CN106459025B (zh) 6-[(4r)-4-甲基-1，1-二氧化-1，2，6-噻二嗪烷-2-基]异喹啉-1-腈的结晶形式
JP2020528912A (ja) シチシン塩、シチシン塩の溶媒和物または水和物、シチシン塩の製造方法、医薬組成物、および治療方法
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
WO2012055163A1 (zh) 来曲唑i型结晶及其制备方法
JP2005511611A (ja) インテグリン受容体拮抗薬のアミン塩
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
CN102666528A (zh) 晶体cdc7 抑制剂盐
CN109721557A (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
TW202102508A (zh) 激酶抑制劑之多晶型、含有該化合物之醫藥組成物、製備方法、及應用
US20260116853A1 (en) New n,n-dimethyltryptamine salts and crystalline salt forms
JP7671362B2 (ja) 医薬組成物、その製造方法及び使用
HK40061155A (en) Amorphous pi3k inhibitor and pharmaceutical composition comprising same
CN109721558A (zh) 来曲唑晶iii型固体物质及制备方法和其药物组合物与用途
HK1234032A1 (en) Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
CN104666304A (zh) 一种复方氯沙坦钾氢氯噻嗪晶体化合物药物组合物
CN104644643A (zh) 一种复方氢氯噻嗪晶体化合物缬沙坦药物组合物
TW200951107A (en) Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1234032

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20190528

CF01 Termination of patent right due to non-payment of annual fee